



## Prescient signs CAR-T agreement with Peter MacCallum Cancer Centre

- Peter Mac to assist development of OmniCAR platform for next generation CAR-T programs
- Professor Phil Darcy, a global leader in oncology and CAR-T, will lead development program
- Awarded \$100k grant funding from the Federal Government's Innovation Connections scheme
- The new CAR-T agreement adds to Prescient's existing and related research program with Peter Mac into Cell Therapy Enhancements
- OmniCAR seeks to make CAR-T more controllable and adaptable, and by doing so, broaden CAR-T's application, particularly into solid tumours

**MELBOURNE Australia 10 May 2021:** Prescient Therapeutics Limited (ASX: PTX) ("Prescient"), a clinical stage oncology company developing personalised medicine approaches to cancer, today announced a new research program with the world-renowned Peter MacCallum Cancer Centre (Peter Mac) to advance its next-generation CAR-T programs utilising the OmniCAR platform.

As announced to the market last year [14/8/2021], Prescient has an existing research agreement with Peter Mac focusing on Cell Therapy Enhancement programs, which seeks to improve current generation CAR-T approaches. The new agreement announced today expands the Prescient and Peter Mac research relationship to include development of the next generation OmniCAR platform.

Prescient is developing three OmniCAR programs internally, including next-generation CAR-T therapies for acute myeloid leukaemia (AML); Her2+ solid tumours and glioblastoma multiforme (GBM). Prescient is developing OmniCAR as a CAR-T platform, capable of being deployed by other CAR-T and oncology companies under licence to advance their own programmes.

Under the terms of the Peter Mac OmniCAR contract research agreement, Prescient will have access to the world-class expertise and facilities of Peter Mac, led by international CAR-T expert, Professor Phil Darcy, to undertake part of the OmniCAR preclinical development programs.

Prescient will own any resulting intellectual property from the work.

Prescient's partnership with Peter Mac now includes two post-doctoral scientists and two research assistants who are dedicated full time to Prescient work. Prescient has also secured grant funding of \$100,000 from the Federal Government's Innovation Connections scheme towards this research.



## Peter Mac is a Global Leader in CAR-T

Peter Mac is at the global forefront of CAR-T treatment, research and manufacturing. Cell Therapies Pty Ltd – which is based at the Melbourne site of majority shareholder Peter Mac – is the Asia Pacific region's only manufacturer of approved CAR-T therapies. In 2019, Peter Mac's Centre of Excellence in Cellular Immunotherapy attracted \$105 million – including \$80 million from the Federal Government – to establish a dedicated CAR-T clinical unit and expand capacity for CAR-T manufacturing and clinical trials.

CAR-T is a revolutionary cancer treatment that involves removing immune cells from a cancer patient, reprogramming them in a lab to recognise and attack cancer cells and then infusing them back into the patient. Current generation CAR-T therapies have demonstrated unprecedented efficacy in certain blood cancers, but face several challenges, including manufacturing costs and logistics, safety, control and limitations in targeting solid tumour cancer antigens.

Prescient's OmniCAR platform, a next-generation modular CAR-T platform, seeks to overcome the limitations of current generation CAR-T approaches by giving clinicians greater control, safety, flexibility and efficacy as well as the potential to improve CAR-T performance against solid tumours.

**Steven Yatomi-Clarke, CEO and Managing Director of Prescient, said:** "We are delighted to deepen our ties with a world-class institute in Peter Mac. Prescient is committed to developing all three OmniCAR programs expediently, and to the highest standard. This latest research program with Peter Mac is an important part of Prescient's development plans, which include institutional and commercial laboratories. We continue to work very closely with Professor Darcy and the team at Peter Mac as we progress this exciting development of controllable and adaptable next generation CAR-T therapies."

**Professor Phil Darcy said:** "CAR-T is a breakthrough treatment that can be life-saving for blood cancer patients who have limited treatment options, and the great challenge now is to find a way to replicate this in solid tumours. We are excited by the opportunity and potential offered by the OmniCAR platform to make headway into solid tumours and other blood cancers, and to greatly enhance and improve the clinical control and efficacy of existing CAR-T cancer therapies."

**- Ends -**

**To stay updated with the latest company news and announcements, please update your details on our investor centre: <https://prescienttherapeutics.investorportal.com.au/>**

## About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

### **Cell Therapies**

**OmniCAR:** is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.



The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens.

OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Prescient is developing OmniCAR programs for next-generation CAR-T therapies for Acute Myeloid Leukemia (AML); Her2+ solid tumours, including breast, ovarian and gastric cancers; and glioblastoma multiforme (GBM).

**Cell Therapy Enhancements:** Prescient has several other initiatives underway to develop new cell therapy approaches.

### **Targeted Therapies**

**PTX-100** is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only RhoA inhibitor in the world in clinical development. PTX-100 is currently in a PK/PD basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. In a previous Phase 1 trial in advanced solid tumours, PTX-100 was well tolerated and achieved stable disease.

**PTX-200** is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound has previously generated encouraging Phase 2a data in HER2-negative breast cancer and Phase 1b in recurrent or persistent platinum resistant ovarian cancer, with a Phase 1b/2 trial currently underway in relapsed and refractory AML.

The Board of Prescient Therapeutics Limited has approved the release of this announcement.

Find out more at [www.ptxtherapeutics.com](http://www.ptxtherapeutics.com), or connect with us via Twitter @PTX\_AUS and LinkedIn.

To stay updated with the latest company news and announcements, please update your details on our investor centre: <https://prescienttherapeutics.investorportal.com.au/>

Steven Yatomi-Clarke  
CEO & Managing Director  
Prescient Therapeutics  
[steven@ptxtherapeutics.com](mailto:steven@ptxtherapeutics.com)

**Investor enquiries:**  
Warrick Lace – Reach Markets  
+61 404 656 408  
[warrick.lace@reachmarkets.com.au](mailto:warrick.lace@reachmarkets.com.au)

**Media enquiries:**  
Andrew Geddes – CityPR  
+61 2 9267 4511  
[ageddes@citypublicrelations.com.au](mailto:ageddes@citypublicrelations.com.au)



## Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

## Supplemental COVID-19 Risk Factors

Please see our website : [Supplemental COVID-19 Risk Factors](#)